Headquartered in Mentor, OH Fiscal year ends March NYSE: STE steris.com
STERIS plc is a global provider of infection prevention products and services serving healthcare facilities, pharmaceutical and biotechnology companies, and medical device manufacturers. The company operates through three segments: Healthcare, which provides sterilization and surgical products, consumables, and services to hospitals and other healthcare providers; Applied Sterilization Technologies (AST), which offers contract sterilization and laboratory services to medical device and pharmaceutical companies; and Life Sciences, which supplies sterilization, disinfection, and cleaning consumables and equipment to pharmaceutical and research customers. STERIS generates approximately 73% of its revenue from the United States, with international operations contributing the remainder. The company's recurring revenue model, encompassing consumables and services, represents the majority of total revenue. Updated
Monday's top analyst upgrades and downgrades included Altria, Archer Daniels Midland, Baidu, Beyond Meat, Bunge, General Electric, Hecla Mining, Kraft Heinz, Lowe’s Companies, Mosaic, Philip Morris International, Rivian Automotive, SLM, Sunrun, Toast,…
Returning capital to investors shows that a company is doing well and has the earnings and cash flow strength to increase the payouts. Five top companies are expected to hike their dividends…
Thursday's top analyst upgrades, downgrades and initiations include Twitter, Whiting Petroleum, Groupon, Goldman Sachs BDC and AT&T.
ThinkstockWhen short interest, or the amount of any specific stock sold short, starts to decline, that is usually a flashing sign for investors to take a look behind the curtain. In general,…
There was a much larger list of companies which hit 52-week lows, but these were some of the larger percentage changes that we looked at: Amylin Pharmaceuticals Inc. (AMLN) closed at $29.34…
Douglas A. McIntyre STERIS plc is a global provider of infection prevention products and services serving healthcare facilities, pharmaceutical and biotechnology companies, and medical device manufacturers.
24/7 Wall St.'s 12-month price target for STE is $262.29, rated Buy. The Wall Street consensus target is $263.12. STE price prediction →
